Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 58 |
| Active Pipeline (Recruiting Now) | 16 (9) |
| Completed vs Stopped Early | 33 / 9 (15.5%) |
| Median Closed Actual Enrollment | 272 participants |
| Physical Hospital Site Disclosure | 46.1% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of South Florida | Tampa, FL | 5 |
| ProScience Research Group | Culver City, CA | 5 |
| Oregon Health and Science University Knight Cancer Institute | Portland, OR | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06971731 | A Study of JNT-517 in Participants With Phenylketonuria (PKU) | Phase III | RECRUITING |
| NCT06628128 | A Long-Term Study of JNT-517 in Participants With Phenylketonuria | Phase III | RECRUITING |
| NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Phase III | RECRUITING |
| NCT04782258 | A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive | Phase III | RECRUITING |
| NCT07759154 | A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Otsuka Pharmaceutical Development & Commercialization Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.